CAJ | 학술논문

目的：探讨Latexin（ LXN）蛋白在胃癌组织中的表达及其与胃癌临床病理特征和预后的关系。方法采用组织芯片和免疫组织化学技术检测143例胃癌及对应癌旁组织中LXN蛋白的表达情况，分析其与临床病理特征及总生存期（ OS）的关系。结果胃癌组织中LXN的阳性表达率为60?1％（86／143），低于癌旁组织100?0％（143／143），差异有统计学意义（ P＜0?05）。 LXN蛋白表达与N分期（ P＝0?005）和组织分化（ P＝0?023）有关，与年龄、性别、肿瘤大小、T分期、TNM分期无关。全组患者的中位OS为56?0个月；LXN阳性表达者的中位OS为79?5个月，长于阴性表达者的27?0个月（ P＜0?05）。多因素分析显示仅肿瘤大小是影响胃癌预后的独立因素（ P＝0?018）。结论 LXN在胃癌组织中表达下调，且与部分临床病理特征有关，在一定程度上反映了胃癌的不良预后。
목적：탐토Latexin（ LXN）단백재위암조직중적표체급기여위암림상병리특정화예후적관계。방법채용조직심편화면역조직화학기술검측143례위암급대응암방조직중LXN단백적표체정황，분석기여림상병리특정급총생존기（ OS）적관계。결과위암조직중LXN적양성표체솔위60?1％（86／143），저우암방조직100?0％（143／143），차이유통계학의의（ P＜0?05）。 LXN단백표체여N분기（ P＝0?005）화조직분화（ P＝0?023）유관，여년령、성별、종류대소、T분기、TNM분기무관。전조환자적중위OS위56?0개월；LXN양성표체자적중위OS위79?5개월，장우음성표체자적27?0개월（ P＜0?05）。다인소분석현시부종류대소시영향위암예후적독립인소（ P＝0?018）。결론 LXN재위암조직중표체하조，차여부분림상병리특정유관，재일정정도상반영료위암적불량예후。
Objective To investigate the expression of latexin( LXN) in gastric cancer and determine the relationship of its expression with clinical features and prognosis. Methods The expression level of LXN was detected by tissue microarray technology and immunohistochemistry in 143 cases of gastric cancer and paired adjacent normal tissues. The relationship between the expression of LXN and clinical parameters were analyzed as well as overall survival( OS) . Results The positive rate of LXN in gastric cancer tissues was 60?1%( 86/143) , lower than 100?0%( 143/143) of para?carcinoma tissues( P<0?05) . A significant correlation was observed be?tween the expression of LXN and N stage(P=0?005), tumor differentiation(P=0?023), but not with age, gender, tumor size, T stage and TNM stage. The medium OS of 143 patients was 56?0 months,and for the patients with LXN negative expression was 27?0 months, shorter than 79?5 months of LXN positive expression( P<0?05) . Multivariate analysis revealed that tumor size was the inde?pendent prognostic factor in gastric cancer patients( P=0?018) . Conclusion LXN is down?regulated in gastric cancer and may relate to tumorgenesis and development. Loss of LXN expression is associated with the poor prognosis of gastric cancer.